In Vivo Preclinical Imaging - An Essential Tool in Translational Research By Dr John Comley In vivo imaging of small animals (mainly mice) is increasingly being deployed across the drug development process, particularly in the oncology/cancer therapeutic area. One of the main applications is monitoring the treatment response for early… Read More
Next Generation Flow Chemistry and Biology Platforms: The Impact on Small Molecule Drug Discovery By Dr J Mark Treherne, Dr David M Parry and Christopher N Selway Can the next generation of flow chemistry and biology platforms be fully integrated to transform the efficiency of small-molecule drug discovery for pharmaceutical… Read More
Share Share Tweet Email What Are The Obstacles to Innovation in the Pharmaceutical Industry? What Are The Obstacles to Innovation in the Pharmaceutical Industry? The Pistoia Alliance Innovation is a key word throughout the pharmaceutical industry and the healthcare community and its pursuit is a business imperative for Pharma. Pharma… Read More
In Vivo Cell Reprogramming: Current status and potential clinical applications By Dr Shili Wu, Jonathan Pang, Bobby Baravati, Jun Bao and Dr Yong Zhu In Vivo Cell Reprogramming, or IVR, is a new technology that can be used to develop cures for incurable diseases. Using a combination of protein, small… Read More
3D Cell Culture Developments to Improve In Vitro Analyses By Prof Stefan Przyborski Improved in vitro models are required to aid the identification and assessment of candidate molecules for pharmaceutical development. Conventional cell culture models involve the growth of cells on two-dimensional (2D) substrates. Cells adapt to this synthetic 2D… Read More
The Post Genomic Era: What Does It All Mean? By Dr Chris Torrance Information may no longer be a bottleneck to understanding and tackling complex genetic diseases such as cancer. For those who cut their research teeth not so very long ago, before PCR was thought of by Kary Mullis,… Read More
Epigenetics: An Emerging Target Class for Drug Screening By Dr John Comley Heightened awareness of the potential importance of epigenetic targets in many disease areas, and growing vendor interest in developing new assays to screen DNA methylation and histone modifications encouraged HTStec to undertake market research in this area in… Read More
The Benefits Of Drug Repositioning By Dr Aris Persidis Drugs in development, on the market, or those that are shelved because of lack of efficacy, are excellent starting points for further development. Finding new indications for such drugs will benefit patients who will see a potential new therapy sooner, will… Read More
Protein Biomarker Immunoassays: Opportunities and Challenges By Dr M. Walid Qoronfleh and Dr Klaus Lindpaintner With the biopharma industry under heavy pressure, transforming the scientific interchange between the laboratory and the clinic is exceedingly critical. Realising the costly toll of drug attrition in late-stage development, many companies are turning to… Read More
Induced Pluripotent Stem Cells: A model for transforming drug discovery By Dr Dwight Morrow and Dr Julie Holder Induced pluripotent stem (iPS) cells have the potential to transform drug discovery by providing physiologically relevant cells for toxic compound identification, target validation, compound screening, and tool discovery. The technology for generating… Read More
Moving Forward With Label-Free Technology By Dr Jennifer Hartigan, Cindy Liu and William Downey Label-free technology is gaining acceptance and opening doors for new drug discovery. Relatively new in the well-established world of high throughput screening (HTS), label-free technology provides opportunities for probing biomolecular interactions without spatial-interference, auto-fluorescent or quenching… Read More
New Mechanisms and Expanded Indications for Biologic Therapies: a perspective on immunology research and development By Dr Susan B. Dillon Over the past decade, the introduction of biologic therapies has had a profound impact for millions of patients with immune-mediated arthritides, inflammatory bowel diseases and plaque psoriasis. Today, five anti-Tumor… Read More
Current Trends in Label-Free Drug Discovery Technologies By Philip Rawlins Drug Discovery Label-free technologies have been used throughout drug discovery for the detection and characterisation of molecular interactions. The implementation of automated systems, increased sensitivity and the development of new technologies have recently broadened the use of label-free methods from… Read More
Mass Spectrometry is a mature technology predicated on a premise demonstrated almost a century ago. It is widely used in most scientific disciplines involving basic research or industrial endeavours, that require accurate and precise measurement of elemental and molecular components. More recently it has become one of the foundation technologies… Read More
Overcoming Bottlenecks in Drug Discovery By Dr Trevor Perrior Developing a new drug is an expensive and time-consuming process. The best current estimate puts the cost of developing a single new drug at close to $1 billion. After a drug candidate has entered the clinical trial process it takes, on… Read More
High Throughput Flow Cytometry for Discovery at UNMCMD and the NIH Molecular Libraries Initiative By Dr Larry A. Sklar and Dr Bruce S. Edwards Commercial flow cytometers became widely established in research and clinical laboratories in the 1980s. Once the domain of immunologists and hematologists for cell sorting and analysis,… Read More